Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression

开发用于治疗慢性抑郁症的腺苷 A1 受体激动剂 MRS5474

基本信息

  • 批准号:
    10220705
  • 负责人:
  • 金额:
    $ 93.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Depression is a common mental disorder, which can be chronic or recurrent, markedly tarnishing a person’s ability to function in their normal life. People with a depression can feel empty, sad, helpless, restless, hopeless, anxious, worthless, guilty, irritable, ashamed or suicidal. They may lose interest in routine work or physical activities. They show appetite disorder, problems concentrating, remembering details or making decisions. It has also been shown that healthy people may exhibit sub-clinical levels of depressive symptoms. Because of their impact on the society and widespread prevalence, depressive symptoms are a significant public health concern. Nearly 20% of the population, show depression-like symptoms at some point in their lives. Currently, there are 350 million people worldwide and 16 million people in the US affected by depression, and the scope of the population affected by depression is gradually expanding. The estimated market for antidepressants was $14.51 billion and will grow to $16.8 billion by the year 2020. Despite recent advances in pathophysiological hypotheses such as alterations in neuroplasticity, neurogenesis, and neuroimmunological regulation, current treatments lack rapid clinical efficacy limiting the ability, for example, to bring instant relief needed with suicidal patients. Therefore, there is a need for the rapid treatment of depression. The adenosine signaling pathway activated by sleep deprivation has shown rapid benefits in preclinical and clinical studies. In particular, sleep deprivation upregulates adenosine A1 receptors (A1R) in mice and humans. Dr. Jacobson and his group have identified a compound MRS5474 as a potent small- molecule A1R agonist with exceptional drug-like properties. It is metabolically stable, orally bioavailable and has an excellent safety profile in mice. Our collaborator, Dr. Biber, has shown that A1R knockout mice exhibit an increased depressive-like behavior and were resistant to the antidepressant effects of sleep deprivation. In contrast, he demonstrated that upregulation of A1R had pronounced acute and chronic resilience toward depressive- like behavior in various tests. Furthermore, they also showed that increased expression of homer1a is a final common pathway mediating the antidepressant effects of different antidepressant treatments including the A1R agonist. The A1R agonist MRS5474 induced a rapid antidepressant effects in animal models of transgenic mice with intraperitoneal (IP) administration. In summary, MRS5474 has great potential to be a rapid, efficacious and safe antidepressant with a unique mechanism of action. The expression of Homer1a and ERK1,2 will serve as biomarkers for preclinical and clinical studies. In this Fast-Track proposal, we will first establish that 1) MRS5474 has good BBB penetration (Brain/Plasma ratio ≥ 1), 2) direct relationship between exposure of MRS5474 and effects on Homer1a expression levels and ERK activity, 3) A1R antidepressant effects of MRS5474 in the CDM with oral administration and 4) an excellent safety profile. In the Phase II, we will continue with IND enabling studies to ensure that MRS5474 has all the attributes to become a successful antidepressant drug and will file IND application for clinical trials.
抑郁症是一种常见的精神障碍,可以是慢性的,也可以是复发性的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Janak K Padia其他文献

Janak K Padia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Janak K Padia', 18)}}的其他基金

Development of PTLS-209 for treatment for giardiasis
开发用于治疗贾第鞭毛虫病的 PTLS-209
  • 批准号:
    10849944
  • 财政年份:
    2022
  • 资助金额:
    $ 93.5万
  • 项目类别:
Development of PTLS-209 for treatment for giardiasis
开发用于治疗贾第鞭毛虫病的 PTLS-209
  • 批准号:
    10483491
  • 财政年份:
    2022
  • 资助金额:
    $ 93.5万
  • 项目类别:
Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression
开发用于治疗慢性抑郁症的腺苷 A1 受体激动剂 MRS5474
  • 批准号:
    9797678
  • 财政年份:
    2018
  • 资助金额:
    $ 93.5万
  • 项目类别:

相似国自然基金

细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
  • 批准号:
    81570244
  • 批准年份:
    2015
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
  • 批准号:
    81171113
  • 批准年份:
    2011
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目

相似海外基金

Allostery-driven G protein selectivity in the adenosine A1 receptor
腺苷 A1 受体中变构驱动的 G 蛋白选择性
  • 批准号:
    BB/W016974/1
  • 财政年份:
    2023
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Research Grant
Allostery-driven G protein selectivity in the adenosine A1 receptor
腺苷 A1 受体中变构驱动的 G 蛋白选择性
  • 批准号:
    BB/W014831/1
  • 财政年份:
    2022
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Research Grant
Investigation of the relationship among Adenosine A1 receptor activity and HRV
腺苷A1受体活性与HRV关系的研究
  • 批准号:
    20K09341
  • 财政年份:
    2020
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Changes in adenosine A1 receptor-mediated regulation of hippocampal area CA2 following chronic high-dose caffeine treatment during adolescence in rats
大鼠青春期长期大剂量咖啡因治疗后腺苷 A1 受体介导的海马区 CA2 调节的变化
  • 批准号:
    BB/P008143/2
  • 财政年份:
    2019
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Research Grant
Adenosine A1 receptor modulation: Structure, dynamics & novel pharmacological interventions
腺苷 A1 受体调节:结构、动力学
  • 批准号:
    nhmrc : GNT1145420
  • 财政年份:
    2018
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Project Grants
Adenosine A1 receptor modulation: Structure, dynamics & novel pharmacological interventions
腺苷 A1 受体调节:结构、动力学
  • 批准号:
    nhmrc : 1145420
  • 财政年份:
    2018
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Project Grants
Changes in adenosine A1 receptor-mediated regulation of hippocampal area CA2 following chronic high-dose caffeine treatment during adolescence in rats
大鼠青春期长期大剂量咖啡因治疗后腺苷 A1 受体介导的海马区 CA2 调节的变化
  • 批准号:
    BB/P008143/1
  • 财政年份:
    2017
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Research Grant
Understanding mechanisms of allostery and biased agonism at the adenosine A1 receptor
了解腺苷 A1 受体的变构和偏向激动机制
  • 批准号:
    nhmrc : 1084246
  • 财政年份:
    2015
  • 资助金额:
    $ 93.5万
  • 项目类别:
    Project Grants
Analgesic actions of adenosine A1 receptor along axonal tracts in chronic pain
腺苷 A1 受体沿轴突束对慢性疼痛的镇痛作用
  • 批准号:
    9101984
  • 财政年份:
    2013
  • 资助金额:
    $ 93.5万
  • 项目类别:
Analgesic actions of adenosine A1 receptor along axonal tracts in chronic pain
腺苷 A1 受体沿轴突束对慢性疼痛的镇痛作用
  • 批准号:
    9294975
  • 财政年份:
    2013
  • 资助金额:
    $ 93.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了